Murine Leukemia Virus (MLV) Related Human Retroviruses and Blood Safety BPAC meeting, December 14, 2010 Indira Hewlett, Ph. D Chief, Laboratory of Molecular.

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
Blood XMRV Scientific Research Working Group Mission - design and coordinate research studies to evaluate whether XMRV poses a threat to blood safety Working.
In latent infection- retroviral genome is present but is not transcribing viral genome or mRNA for structural proteins. Distinguished by qPCR (DNA) and.
Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.
Screening of Human and Animal Sera from Egypt and Hong Kong Perera et al. Euro Surveill. 2013;18(36):pii=20574 Sampled 1343 Human, 625 animals.
Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Identification of the New Human Retrovirus XMRV. Disclosures Research Support –Abbott Laboratories Patent Licenses and Consulting –Abbott Laboratories.
See using a flow cytometry assay expression of 3 goat poly clonal antibodies to purified viral proteins in both T and B cells but not in T cells from a.
CDC Investigations Relevant to Potential for Simian Foamy Virus Transmission by Transfusion Louisa Chapman, MD, MSPH OD, DASTLR, NCID, CDC & HIV and Retrovirology.
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Evidence for the presence of XMRV in 33 PCR Negative US CFS Patients 19/33 Antibodies in the plasma 30/33 Transmissable virus in the plasma 10/33 Protein.
Detection of XMRV/pMuLV Infections in Patients with Chronic Fatigue Syndrome and Healthy Blood Donors Shyh-Ching Lo, Ph.D., M.D. Division of Cellular and.
Dengue Virus and Its Risk to the U.S. Blood Supply
1 Babesia BPAC: FDA Perspective Sanjai Kumar, PhD Division of Emerging and Transfusion- Transmitted Diseases Office of Blood Research and Review CBER,
Blood XMRV Scientific Research Working Group Funding for currently launched studies via NHLBI REDS-II Program Central Lab BSRI - Graham Simmons NAT Lab.
HIV Testing CDC power point edited by M. Myers
Update on CDC XMRV Activities R. Michael Hendry, D.Sc. Chief, Laboratory Branch DHAP, NCHHSTP, CDC Blood Products Advisory Committee July 26, 2010 The.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
Division of Emerging and Transfusion Transmitted Diseases Bioterrorism Preparedness Initiatives Hira L. Nakhasi, Ph.D.
Deferral of MSM by Andrew I. Dayton, M.D., Ph. D. The HIV epidemic in the U.S.A. is generally recognized to have started just after Currently MSM.
Measles Antibody Levels in U.S. Immune Globulin Products
Dr. Peter R. Ganz Director, Centre for Blood and Tissues Evaluation, Health Canada Strategies for Managing Potential Xenotropic Murine Virus Related Virus.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
BioLife Plasma Services Experience with HBV NAT Testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.
Xenotropic Murine Leukemia Virus Related Virus (XMRV) Informational Presentation BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
Long Term Follow Up of Subjects in Gene Transfer Clinical Trials Philippe Bishop, MD FDA/CBER Division of Clinical Trial Design and Analysis Oncology Branch.
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.
Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Perspectives on XMRV and Related Retroviruses John M. Coffin Endogenous proviruses Receptor usage Endogenous proviruses Receptor usage HIV Drug Resistance.
An Update on FDA/OBRR XMRV activities BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of Molecular Virology DETTD/CBER/FDA.
Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Xenotropic Murine Leukemia Virus-Related Retrovirus: CCR Assay Development.
1 B19 Testing of Plasma for Fractionation: Current Thinking Mei-ying W Yu, PhD Division of Hematology CBER/FDA SoGAT XVII May 26-27, 2004.
Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.
Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.
19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist CHIRON Submission To FDA TSE Advisory Committee Meeting.
Issues Related to Implementation of Blood Donor Screening for Infection with Trypanosoma cruzi Presentation to BPAC April 26, 2007 Robert Duncan, PhD.
Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.
Update Rapid HIV Test Approval Requirements and Standards BPAC September 15, 2000 Kimber Poffenberger, Ph.D.
1 Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting Detection of Porcine circovirus (PCV) and PCV DNA Sequences in U.S. Licensed.
Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
CBER Overview of Laboratory of Molecular Virology Indira Hewlett, Ph.D Laboratory Chief.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Public Health Perspective on SARS Diagnostics Stephen M. Ostroff Deputy Director National Center for Infectious Diseases, CDC.
CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.
Transfusion Related Acute Lung Injury (TRALI)
Proposed Animal Study to Evaluate Simian Foamy Virus (SFV) Transmission by Blood Arifa S. Khan, Ph.D. DVP, OVRR, CBER, FDA BPAC, December 13, 2001.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.
Diagnostic Testing for Zika Virus Frederick S. Nolte, PhD, D(ABMM), F(AAM) Professor and Vice-Chair for Laboratory Medicine Department of Pathology and.
Hereditary Cancer Predisposition: Updates in Genetic Testing
Update on CBER HIV-1 Subtype panel
Rapid Detection of HIV-1 subtype C Integrase resistance mutations by the Use of High-Resolution Melting Analysis Tendai Washaya BSc, Msc. Pre-PhD Student.
Presentation transcript:

Murine Leukemia Virus (MLV) Related Human Retroviruses and Blood Safety BPAC meeting, December 14, 2010 Indira Hewlett, Ph. D Chief, Laboratory of Molecular Virology DETTD/CBER/FDA

Issue FDA is seeking the advice of the BPAC on  1) donor deferral based on a history or diagnosis of Chronic Fatigue Syndrome (CFS) or Prostate Cancer (PC) and,  2) testing for the newly identified MLV related retroviruses in humans recognizing that disease causation has not been established.

Identification of MLV related retroviruses in humans 3 Prostate Cancer Tissue DNAVirochip Urisman A, et al. PLoS Pathogen 2006; 2(3): e25 Silverman R, et al. Nat. Rev. Urol 2010; Schlaberg R, et al. PNAS 2009; 106(38): Lo S, et al. PNAS 2010; 107(36): polytropic MLV xenotropic MLV

MLV/XMRV and Blood Safety  In 2009, a US study reported XMRV detection in blood of 67% (68/101) of CFS patients and 3.7% (8/218) of healthy controls using PCR.  XMRV and MLV-related human retroviruses have since been detected in the blood of 0-14% of healthy controls.  However, several studies have shown lack of MLV/XMRV detection in CFS, PC and blood donors.  Although disease association has been reported, causation has not yet been established.

July 2010 BPAC Informational Session Topics discussed :  Identification and detection (or lack of) in CFS, PC blood donors.  Assay validation study plans and assay development efforts.  AABB recommendation for use of donor education materials on CFS and indefinite deferral for donors who voluntarily disclose their CFS diagnosis.  Health Canada’s policy of indefinite deferral for PC and recent introduction of deferral for those who voluntarily disclose their CFS diagnosis.

Update on MLV/XMRV Disease Association – CFS Lo et al, PNAS, Aug  32/37 (86.5%) of CFS patients positive for polytropic MLV-related sequences by PCR on PBMC DNA  3/44 (6.8%) of US healthy volunteer blood donors positive by PCR on PBMC DNA. Hanson et al, 1 st Intl. Workshop on XMRV, Sept  MLV related sequences detected in PBMC DNA of 8/10 severe CFS, 3/10 recovered CFS cases and 1/10 healthy controls.  Virus isolated from plasma of 6 individuals including 5 CFS patients. Mikovits et al, 1 st Intl. workshop on XMRV, Sept  50 CFS patients in UK, PCR, culture and serology; > 60% positive for XMRV by culture and serology.

Lack of Disease Association – CFS AuthorCountryNo. of SamplesDetection MethodsReference Switzer B, et alUSA51 CFS cases 53 healthy controls 41 U.S. blood donors Nested PCR, WB, ELISA, IFA (Done in three labs) Retrovirology 2010; 7:57 Henrich TJ, et alUSA32 CFS 261 controls PBMC DNA; nested PCRJ Infect. Dis 2010; 202: Van Kuppeveld FJM, et al Netherlands32 CFS pts 43 controls Nested PCR of gag gene. Real time PCR of integrase BMJ. 2010; 340: c1018. Groom HC, et alUK170 CFS patients 395 controls PCR or real time PCR Viral neutralization assay for XMRV and MLV. Retrovirology. 2010; 7:10 Hong P, et al.China65 CFS patients 85 blood donors RT PCR PBMCs and plasma Virology Journal. 2010; 7:224. Hohn O, et alGermany36 CFS 50 MS with fatigue 30 controls Gag & env ELISAs Nested PCR 1 st International Worskshop XMRV Blomberg JSweden40 CFS plasma 50 CFS PBMCs 200 controls RT qPCR Integrase, Gag & env PCR Serology, virus culture 1 st International Worskshop XMRV. 2010

 Petros et al, 1 st Intl. Workshop on XMRV, Sept  3 PC tissues from 3 separate PC patients tested and found to be positive for XMRV/MLV sequences by PCR.  Fischer et al, 1 st Intl. Workshop on XMRV, Sept  355 PC tissue, 40 PBMC from PC patients and 70 healthy controls from Northern Europe tested by PCR;  2/355 (0.56%) tissues positive for XMRV, 1 wild type and 1 heterozygous for R462Q.  PBMC from 2 XMRV positive PC patients negative by PCR.  All healthy controls negative for XMRV sequences.  Danielson et al, JID, epub Oct  Prostatic tissue of 144 PC patients from southern US by PCR for the env gene; 32/144 (22%) positive for XMRV sequences.  Both normal and tumor tissue for 57 cases tested; 21/57 (36.8%) normal and 25/57 (43.9%) tumor tissue samples positive for XMRV. Disease association - PC

Lack of Disease Association – PC AuthorCountryNo. of SamplesDetection MethodsReference Aloia, et alUSA161 tumor derived samples (PCR); 596 tumor tissue samples (IHC) 452 benign prostatic tissue samples (IHC) Nested RT-PCR IHC Cancer Research 2010; Oct 21. [Epub ahead of print] D’Arcy F, et alIreland139 PCnested PCREuropean Urology 2008; 7(suppl):271 Hohn O, et alGermany589 PC tissue samples 146 PC serum samples Gag & env ELISAs Nested PCR Retrovirology 2009;6:92 Blomberg etalSweden400 PC patientsRT-qPCR, gag, env PCR, serology, virus culture 1 st International Worskshop XMRV

Evaluation of Transfusion Risk  Transfusion transmission of MLV/XMRV theoretically possible due to presence in blood cells, evidence of cell-free virus (Lombardi et al, 2009).  Low but detectable transient viremia in rhesus macaques 4-14 days and seroconversion days post intravenous inoculation (Qiu et al, 2010).  Sero-prevalence of 1.7% (5/300) in Japanese blood donors; 0.1% (3/2861) in US blood donors (Qiu et al, 2010) and 6.8% (3/44) positive by PCR on PBMC DNA (Lo et al, 2010).  However, no evidence of XMRV in 1) US study of 121 blood donors by PCR and serology (Switzer et al, 2010) and 2) different US study of 1435 HIV-ve and 44 HIV-1 +ve blood donors by TMA ( Gao et al, 2010).  No XMRV sequences in 105 plasma and 19 PBMC from Cameroon blood donors, 94 HIV-1 infected individuals from Uganda (Tang et al, 2010).

Potential Sources of Discrepancies  Study populations and geographic differences in prevalence  Case definition criteria and stage of illness  Specimen processing, sensitivity and specificity of test methods  Potential genetic variation of the virus  Other unknown factors Need for assay standardization and validation to evaluate blood safety and disease association.

Assay validation for blood donor studies  NHLBI Scientific Research Working Group comprised of scientists from govt., academia and blood organizations established to validate assays for transfusion transmission studies.  BSRI’s analytical and clinical reference panels evaluated by multiple labs including CDC, NIH, WPI, BSRI and 2 labs at FDA for testing of blood donors in future studies.  FDA currently developing NAT and serology panels for future lot release, if needed.

NIH sponsored Proposed Study on XMRV and Related Viruses in Chronic Fatigue Syndrome Laboratory sites CDC, NCI, WPI, others Sample preparation TBD time to extraction Clinical collection sites TBD access, expertise, geography Assays molecular, cultivation/co-cultivation Organizational Meeting, 4-5 October 2010 Labs: Harvey Alter (NIH), Bill Switzer (CDC), Judy Mikovits (WPI) Consultants: John Coffin (NCI), Simone Glynn (NHLBI), Suzanne Vernon (CFIDS), Nancy Klimas (U of Miami) Columbia Faculty: Bruce Levin, Mady Hornig, W. Ian Lipkin

NIH sponsored Proposed Study on XMRV and Related Viruses in Chronic Fatigue Syndrome Laboratory sites CDC, NCI, WPI, others Sample preparation TBD time to extraction

MLV/XMRV and Blood Donation  No direct evidence for transfusion transmission or association with a transfusion transmitted disease, therefore, FDA has not established donor policy specific to MLV/XMRV.  FDA regulations require donors to be in good health at time of donation; medical directors exercise judgment on whether CFS patients meet criteria.  In regard to PC, large survey in Sweden and Denmark (SCANDAT) showed no increase in disease cases in 888,843 blood transfusion recipients without a prior cancer diagnosis at the index transfusion.  Indefinite deferral of donors who voluntarily disclose CFS diagnosis in Australia, New Zealand, UK and parts of Canada.  In the US, AABB issued bulletin (No ) recommending use of donor education materials on CFS and indefinite deferral for donors who voluntarily disclose their CFS diagnosis.

Questions for the Committee 1. Do the scientific data support asking donors about a medical history and/or diagnosis of CFS as a basis for indefinite deferral? 2. Please discuss whether the scientific data support asking donors about a medical history and/or diagnosis of prostate cancer as a basis for indefinite deferral.

Questions for the committee – con’t 3. Please comment on the scientific evidence that would be needed to justify a policy of donor testing for infection with MLV-related human retroviruses. In particular, should donor testing be considered in the absence of confirmed disease causation ? 4.Assuming that testing is warranted, please comment on the potential utility of NAT and /or serologic testing of blood donations to ensure safety of the blood supply from transmission of MLV-related human retroviruses.

BPAC presentations The BPAC session today will include the following presentations on MLV/XMRV:  Review of current data on MLV/XMRV including highlights of the Ist International Workshop.  Research updates and current data on association of MLV/XMRV with CFS.  Data from animal infectivity studies.  Update from the Blood Scientific Research Working group on assay validation using MLV/XMRV panels.  Prospective and retrospective donor prevalence studies.  Assay development efforts on MLV-related retroviruses.